JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Janux Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.74+0.23 (+1.39%)
Close on Oct 19, 2026
- Market cap
- $1.05B
- P/E (TTM)
- –
- Dividend yield
- –
Janux Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Janux Therapeutics | Industry median |
|---|---|---|
| Market Cap | $1.02B | $197.05M |
| Enterprise Value | $52.52M | $106.56M |
| PS Ratio | 42.64 | 3.93 |
| PB Ratio | 1.10 | 2.14 |
| P/TBV Ratio | 1.10 | 2.46 |
Enterprise value
| Measure | Janux Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 2.19 | 2.69 |
Income (trailing twelve months)
| Measure | Janux Therapeutics | Industry median |
|---|---|---|
| Revenue | $24.00M | $57.94M |
| Operating Income | -$143.56M | -$21.44M |
| Net Income | -$102.59M | -$22.46M |
| EBITDA | -$143.56M | -$16.91M |
| EPS (Diluted) | -$1.64 | -$0.83 |
Margins
| Measure | Janux Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -598.1% | -44.5% |
| Profit Margin | -427.5% | -39.2% |
| EBITDA Margin | -598.1% | -31.3% |
| FCF Margin | -174.7% | -8.85% |
Returns
| Measure | Janux Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -10.7% | -53.1% |
| Return on Assets (ROA) | -10.1% | -41.0% |
| Return on Capital Employed (ROCE) | -15.2% | -37.8% |
Growth
| Measure | Janux Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 5367.0% | 6.01% |
| Revenue Growth (3Y CAGR) | 5.11% | 2.25% |
Balance sheet
| Measure | Janux Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $970.91M | $62.42M |
| Net Cash (Debt) | $970.91M | $15.68M |
| Net Cash Per Share | $15.88 | $0.65 |
| Equity (Book Value) | $927.98M | $48.79M |
| Book Value Per Share | $15.18 | $1.36 |
| Tangible Book Value | $927.98M | $23.06M |
| Working Capital | $923.19M | $75.77M |
Financial position
| Measure | Janux Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 16.35 | 3.30 |
| Quick Ratio | 16.14 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Janux Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$41.25M | -$12.35M |
| Capital Expenditures | -$674.00K | -$1.06M |
| Free Cash Flow | -$41.93M | -$20.28M |
| FCF Per Share | -$0.69 | -$0.41 |
Efficiency
| Measure | Janux Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.02 | 0.38 |
| Revenue Per Employee | $220.18K | $398.96K |
| Profits Per Employee | -$941.21K | -$732.08K |
| Employee Count | 109 | 73 |
Dividends and yields
| Measure | Janux Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -10.0% | -21.2% |
| FCF Yield | -4.10% | -7.64% |
Shares
| Measure | Janux Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 61,136,800 | 59,128,900 |
| Shares Change (YoY) | 6.21% | 11.1% |
| Shares Change (QoQ) | 0.35% | 0.54% |
| Float | 45,942,600 | 48,744,500 |
| Shares Held by Insiders | 24.9% | 11.8% |
| Shares Held by Institutions | 100.8% | 59.4% |
Scores
| Measure | Janux Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 7.81 | 0.10 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Janux Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.